25 results about "Central sleep apnea" patented technology

The invention discloses a sleep monitoring method and system based on a millimeter wave radar, and a storage medium, and relates to the technical field of millimeter wave monitoring, and the method comprises the steps: carrying out the time-frequency feature extraction and semantic combination of a millimeter wave detection signal and a millimeter wave detection response signal through employing a signal processing and analysis technology based on artificial intelligence; therefore, whether central sleep apnea occurs or not is automatically judged according to fusion representation characteristics of the millimeter wave detection signal and the millimeter wave detection response signal in multiple modes. According to the invention, the millimeter wave radar can carry out monitoring under the condition that the millimeter wave radar is not in contact with a human body, thereby avoiding inconvenience and interference caused by wearing a sensor in a conventional method, and improving the comfort and compliance of a user. Meanwhile, the millimeter wave radar has high time and space resolution, tiny body movement and breathing changes can be accurately detected, comprehensive and detailed analysis is carried out through the artificial intelligence technology, and the sleep apnea problem can be more accurately recognized and analyzed.

The present invention relates to a combination of a noradrenaline reuptake inhibitor and α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and / or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and muscarinic receptor antagonists for the treatment and / or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

The invention belongs to the technical field of medical treatment and health state monitoring, and provides a sleep state evaluation method and system. The method comprises the following steps: acquiring an electroencephalogram signal, an airflow signal and a chest breathing movement signal; according to the chest breathing movement signals, whether the average value of the chest breathing movement signals within a period of time is smaller than a set first threshold value or not is calculated, and if yes, central sleep apnea occurs; according to the airflow signals, whether the average value of the airflow signals within a period of time is smaller than a set second threshold value or not is calculated, and if yes, obstructive sleep apnea occurs; in the central sleep apnea occurrence stage and / or the obstructive sleep apnea occurrence stage, according to the electroencephalogram signal, calculating a time following index of the sleep apnea occurrence period; according to the influence of the time following index in the sleep apnea occurrence period on the vital signs.

An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic nerve through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.

The present invention relates to a process for the preparation of a pharmaceutical dosage form comprising effective and selective TASK-1 and / or TASK-3 channel inhibitors, and the use of the dosage form obtained by said process for the treatment and / or prevention of respiratory disorders, including sleep-related respiratory disorders, such as obstructive and central sleep apnea and snoring.

To provide therapeutic agents for the use in a method for the treatment and / or prophylaxis of sleep-related breathing disorders, such as obstructive sleep apnea, central sleep apnea and snoring.SOLUTION: The present invention relates to α2-adrenoceptor subtype C (α-2C) antagonists, in particular substituted piperidinyl-pyrimidinyl-tetrahydrochinolines of formula (I). In formula (I), X is (A) or (B).SELECTED DRAWING: Figure 1

Systems and methods for controlling breathing of a patient to maintain specified levels of CO2 in arterial blood. In one exemplary embodiment a respiratory conduit is configured to be coupled at one end to a patient interface device that is, in turn, coupled to the patient's breathing airway. The respiratory conduit is configured at the opposing end to be coupled to a pressurized air generating device. A control device is positioned in the respiratory conduit between the patient interface device and the pressurized air generating device and includes one or more vent apertures that allow a predetermined amount of exhaled air from the patient to escape from the respiratory conduit while retaining a predetermined fraction of the exhaled air to reintroduce to the patient during the next inhale. In this manner the system provides for a predetermined percentage of CO2 to be rebreathed by the patient.

A method includes delivering, via a first stimulation element and during a treatment period, stimulation to an upper airway patency-related nerve to cause contraction of upper airway patency-related muscles. The method also may include delivering upon detecting central sleep apnea behavior, via a second stimulation element and during a treatment period, stimulation to a central sleep apnea-related nerve. The method also may include delivering the stimulation to the upper airway patency-related nerve independently of a decisional process and trigger to deliver stimulation to the different central sleep apnea-related nerve.

The present invention relates to the combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I), and muscarinic receptor antagonists, for the treatment and / or prevention of sleep-related respiratory disorders, preferably obstructive sleep apnea and central sleep apnea and snoring.

The present invention relates to alpha2-adrenergic receptor subtype C (alpha-2C) antagonists, in particular 2,3-dihydrobenzo[b][1,4]dioxin-2-ylmethyl)piperazin-1-yl derivatives of formula (I) for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive sleep apnea and central sleep apnea and snoring.

A method includes delivering, via a first stimulation element and during a treatment period, stimulation to an upper airway patency-related nerve to cause contraction of upper airway patency-related muscles. The method also may include delivering upon detecting central sleep apnea behavior, via a second stimulation element and during a treatment period, stimulation to a central sleep apnea-related nerve. The method also may include delivering the stimulation to the upper airway patency-related nerve independently of a decisional process and trigger to deliver stimulation to the different central sleep apnea-related nerve.

Provided are systems, methods and computer-readable media for breathing signal analysis and event detection and systems, methods and computer-readable media for generating respiratory flow and / or effort signals from accelerometer signals using trained models. Breathing signal analysis may characterize at least one recorded signal as indicative of one of Obstructive Sleep Apnea (OSA) and Central Sleep Apnea (CSA). This analysis includes determining a frequency domain representation of an audio signal; sorting at least one frequency interval component into at least one corresponding frequency bin; determining a signal-to-noise ratio (SNR) signal for each frequency bin during a candidate time period; and determining an indication of an OSA event or a CSA event.

The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and norepinephrine reuptake inhibitors for the treatment and / or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and P2X3 receptor antagonists for the treatment and / or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Apparatuses and methods for detecting sleep apnea and classifying the events as obstructive sleep apnea (OSA) and / or central sleep apnea (CSA) are disclosed herein. The apparatuses can include respiratory treatment devices that have an auto adjusting algorithm that is able to classify a sleep apnea as CSA or OSA so that an appropriate pressure can be applied to the patient depending on the type of sleep apnea detected. The apparatuses and methods can use characteristics of at least one breath preceding the apnea event in classifying the event.

The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles of formula (I) for the use in a method for the treatment and / or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 2,3-Dihydrobenzo[b][1,4]dioxin-2-ylmethyl)piperazin-1-yl derivates of formula (I) for the use in a method for the treatment and / or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

The present invention relates to the combination of a noradrenaline reuptake inhibitor and an alpha2-adrenergic receptor subtype C (alpha-2C) antagonist, in particular a substituted heterocyclic carboxamide of formula (I), for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive sleep apnea and central sleep apnea and snoring.

The present application discloses a sleep monitoring method, system and storage medium based on millimeter wave radar, which relates to the field of millimeter wave monitoring technology. It uses artificial intelligence-based signal processing and analysis technology to extract time-frequency features and semantically combine millimeter wave detection signals and millimeter wave detection response signals, so as to automatically determine whether central sleep apnea occurs based on the fusion representation features of the millimeter wave detection signal and the millimeter wave detection response signal in multimodality. In the present application, the millimeter wave radar can monitor without contacting the human body, avoiding the inconvenience and interference of wearing sensors in traditional methods, and improving the user's comfort and compliance. At the same time, the millimeter wave radar has high temporal and spatial resolution, can accurately detect tiny body movements and breathing changes, and uses artificial intelligence technology for comprehensive and detailed analysis, which helps to more accurately identify and analyze sleep apnea problems.

This application discloses a method, controller, sleep monitoring device, and storage medium for determining central sleep apnea. The method includes acquiring real-time cardiac impulse signals, acquiring a first array of data and a second array of data based on the cardiac impulse signals, determining an apnea threshold based on the first array of data, and comparing the second array of data with the apnea threshold. If the absolute values ​​of all values ​​in the second array of data are less than the apnea threshold, then central sleep apnea has occurred. This application adaptively determines an apnea threshold that matches the user's situation. The apnea threshold can comprehensively characterize the user's breathing status under normal breathing conditions in a fine-grained and personalized manner. Then, the second array of data is automatically compared with the apnea threshold to automatically determine whether the user has central sleep apnea, which helps to screen for related disease risks.

Apparatuses and methods for detecting sleep apnea and classifying the events as obstructive sleep apnea (OSA) and / or central sleep apnea (CSA) are disclosed herein. The apparatuses can include respiratory treatment devices that have an auto adjusting algorithm that is able to classify a sleep apnea as CSA or OSA so that an appropriate pressure can be applied to the patient depending on the type of sleep apnea detected. The apparatuses and methods can use characteristics of at least one breath preceding the apnea event in classifying the event.